Use the hyperlinks, where available to access additional clinical trial information.
Phase 1-2 Trial Evaluating Anti-TGFÎ² Agent (SAR439459) or Pomalidomide in Combination With Isatuximab and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM)
Eligible patients will be randomised to receive isatuximab and dexamethasone, in addition to either SAR439459 (experimental arm) or pomalidomide (control arm). This trial will include a screening period of up to 28 days for participants treated in each arm. Patients will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor, whichever occurs first. Patients who discontinue the study treatment prior to documentation of disease progression will be followed-up every 4 weeks until confirmation of disease progression. For patients who discontinue study treatment with confirmed disease progression, follow-up visits will be done every 3 months (12 weeks) from the date of last IMP administration until death or final cutoff date, whichever comes first. Adverse events and survival status will be collected.